Repetitive transcranial magnetic stimulation in the treatment of middle-aged and elderly major depressive disorder: A randomized controlled trial.
Medicine (Baltimore)
; 102(35): e34841, 2023 Sep 01.
Article
en En
| MEDLINE
| ID: mdl-37657019
ABSTRACT
BACKGROUND:
Studies have reported the use of repetitive transcranial magnetic stimulation (rTMS) in patients with major depressive disorder (MDD). However, most studies focus on antidepressant effect of rTMS, but few on cognitive aspects. The present study aimed to explore the effect of rTMS on BDNF levels and cognitive function in the treatment of middle-aged and elderly MDD.METHODS:
This was a randomized controlled trial. A total of 120 elderly patients with MDD treated in The Second Affiliated Hospital of Xi'an Medical University from January 2021 to January 2023 were selected as research subjects. The patients were randomly divided into control group (nâ =â 60, patients received simple oral treatment with escitalopram and sham rTMS) and study group (nâ =â 60, patients received oral treatment with escitalopram combined with rTMS) according to the random number table method. We compared the clinical efficacy, serum BDNF levels, and cognitive function between the 2 groups.RESULTS:
After treatment, the HAMD-17 score in the study group was lower than that in the control group [13.00 (12.00-16.00) vs 17.00 (15.00-19.00), Pâ <â .05], and the RBANS score was higher than that in the control group [166.00 (161.25-171.75) vs 133.00 (130.00-136.75), Pâ <â .05]. The total effective rate of the research group was 95.0%, which was higher than the 82.0% of the control group (Pâ <â .05). The serum BDNF levels [36.00 (33.00-38.00) vs 30.00 (28.00-32.00), Pâ <â .05] and MoCA scores [24.00 (22.00-26.75) vs 23.00 (21.00-25.00), Pâ <â .05] of the study group were higher than those of the control group. There were no significant adverse reactions during the treatment of both groups.CONCLUSIONS:
Compared with oral escitalopram alone, repeated transcranial magnetic stimulation in the treatment of middle-aged and elderly patients with major depressive disorder can further improve the efficacy, and can more effectively improve the BDNF level and cognitive function, with ideal safety.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Trastorno Depresivo Mayor
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Humans
/
Middle aged
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2023
Tipo del documento:
Article
País de afiliación:
China